Relating to biological products.

SB 441 removes two requirements for pharmacies and pharmacists when substituting biological products (like insulin or biologic drugs) for prescribed ones. Specifically, it eliminates the need to inform patients about substitutions and retain substitution records for three years. The bill keeps the core rule that substitutions are only allowed if the FDA deems products interchangeable and the prescriber hasn’t prohibited it. This change simplifies pharmacy processes for biological products while maintaining FDA safety standards. (Note: The bill is still in committee as of June 2025.)